CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines.

The United States government has allocated $590 million to Moderna to develop a vaccine for avian influenza, part of an initiative to address the increasing

Moderna’s current price is less than $20 below the psychologically significant $50 price level. Traders often focus on these round-numbered levels as support and resistance points for a stock. Traders should expect that Moderna will see another surge in buying if the stock remains above $50 for more than two trading sessions.

Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health officials are preparing for the potential of the virus adapting to enable human-to-human transmission.

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme

Funding will also support the expansion of clinical studies for up to five additional subtypes of pandemic influenza

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.

The H5N1 virus is common in wild birds and other animals. While it has not conclusively been found to spread from person to person, the amount of bird flu circulating among animals and humans has alarmed scientists.

Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as concerns about a bird flu pandemic in humans grows.